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ABSTRACT  
Purpose:                                                                                                                          
Monozygotic twins provide an excellent tool to study environmental effects on human health.  
Poly(ADP-ribose) polymerase-1 (PARP-1) is an important enzyme primarily involved in 
DNA repair and genomic stability and is under clinical investigation as a target for anticancer 
therapy. As a part of a PARP pharmacogenetics study elderly male monozygotic twins, one 
healthy and the other with a Trojani grade 3 sarcoma treated with doxorubicin (DOX: 142.5 
mg/m2), were recruited for the study.  
Methods:  
PARP activity and expression was measured in peripheral blood mononuclear cells (PBMCs) 
by methods validated to GCLP standard and used as a pharmacodynamic endpoint for clinical 
trials.  
Results: 
The mean PARP activity for the patient before treatment was 160 pmol PAR/106 cells and 
was similar to that of his brother (130 pmol PAR/106 cells). There was approximately 9-fold 
decrease (P=0.001) in PARP activity in a second sample from the patient taken 21 days after 
the first DOX administration (17 pmol PAR/106 cells) and a decrease in PARP-1 expression. 
Investigations in BALB/C mice revealed that DOX treatment (5 mg/kg) resulted in a 
significant transient decrease in PARP activity after 1 h (63% control, P<<0.05) and 24 h 
(53% control, P<<0.05) but that PARP activity was restored 1 week after DOX treatment 
(86% control, P=0.24). 
Conclusions: 
We showed here that administration of DOX can have a profound effect on the measured 
level of PARP activity and expression in PBMCs from patients and animals. Results obtained 
in clinical trials where PARP activity is used as a pharmacodynamic marker of PARP 
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inhibition could reflect the effect of a chemotherapeutic on PBMCs rather than the 
effectiveness of a tested PARP inhibitor.  
Introduction and aims 
Monozygotic twins, due to identical genetic constitution, uterine and early environment, 
provide an excellent material to study the contribution of genes and the environment on 
human biochemistry, pharmacology and health.  Twin studies can help to identify underlying 
causes of both physical and mental disorders [1] and response to drugs [2].  Large, 
nationwide twin studies can help to define the contributions of nature and nurture to complex 
and multifactorial diseases such as cancer [3].  The identification of areas of study likely to 
be worth investing the substantial resources needed for the larger studies comes from initial 
interesting sporadic observations.  Here, for the first time we investigated PARP activity and 
expression in monozygotic twin brothers excluding any potential genetic factors that could 
affect levels of measured parameters. As a part of a pharmacogenetics study the elderly male 
twins: one with a sarcoma that was treated with doxorubicin (DOX) and the other healthy 
were recruited to the study.    
Soft tissue sarcomas are rare types of cancer accounting for about 1% of adult malignancies 
(cancerbackup.org.uk/Cancertype/Softtissuesarcomas/). Sarcomas are usually treated by a 
surgical excision either alone or in combination with radiotherapy. There are only three 
drugs: DOX, dacarbazine and ifosfamide currently used in treatment that give a relatively 
good response rate of 20% or more in patients with advanced soft tissue sarcomas [4]. 
 DOX (also called adriamycin) is one of the most widely used anticancer agents and has the 
broadest spectrum of activity involving DNA intercalation, free-radical formation, covalent 
DNA binding and inhibition of the topoisomerase II resulting in DNA strand breakage. DOX 
is a widely prescribed chemotherapeutic used to treat many different types of cancers 
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however its use in high-doses is limited by the occurrence of severe side effects such as: 
cardiotoxicity, myelotoxicity, Palmar-plantar erythrodysesthesia [5].  
Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding enzyme activated by DNA 
single and double-strand breaks and involved in DNA repair, genomic stability, transcription 
control, cell death and proliferation. Inhibition, or lack, of PARP-1 results in hyper-sensitivity 
to DNA methylating agents, topoisomerase I poisons and ionising radiation, all used in the 
treatment of cancer [6]. Recent in vivo studies demonstrate that PARP inhibition potentiates 
the antitumour effects of DOX in p53 deficient human breast cancer [7]. 
Analysis of the samples received from the twin subjects allowed us to investigate the inter-
individual variation in PARP activity in subjects with the same genetic background and we 
could also investigate how DOX affects PARP activity in peripheral blood mononuclear cells 
(PBMCs). The observed decrease in PARP activity following DOX treatment in the patient 
was then studied in vivo in mice treated with DOX. 
MATERIALS AND METHODS 
All chemicals and reagents were of the highest quality and supplied by Sigma (Dorset, UK), 
unless indicated otherwise. The PARP inhibitor AG014699 was supplied by Pfizer GRD. The 
10H mouse monoclonal primary antibody was generously supplied by Prof. Alexander 
Bürkle (University of Konstanz, Germany). 
Human subjects 
 The PARP pharmacogenetics study has been reviewed by the appropriate ethics committee 
and has been performed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki. The patient and his healthy twin brother (control subject) were 
consented to donate blood samples under the regulations of local ethics committee. 20 ml or 
less of whole blood was collected from the subjects by venipuncture. Blood from the patient 
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was collected just before the first administration of chemotherapy and 21 days after the first 
administration, just before second cycle of treatment. This was transferred into an EDTA 
blood tubes (BD Vacutainer, Plymouth, UK). PBMCs were then extracted from blood using 
Lymphoprep™ Tube (Axis-Shield, Norway) according to manufacturer’s instructions. The 
cell pellet was resuspended in 500 µl pre-chilled freezing medium (RPMI plus 10% foetal 
bovine serum, FBS) supplemented with 10% DMSO, and 1x Halt protease inhibitor cocktail 
(Thermo Fisher Scientific, Rockford, IL). Samples were stored immediately at -80°C. 
Animals 
The experiments on animals were conducted in accordance with national law and institutional 
guidelines for the care and use of animals under a protocol approved by local ethics 
committee. Male BALB/C mice (8-10 weeks of age, 5 mice/group) were treated as follows: 
untreated controls, and mice treated with 5 mg/kg DOX via intraperitoneal injection (IP) and 
killed 1 h, 24 h and 6 days after treatment. Blood from the 5 animals was pooled to yield 
sufficient sample for lymphopreparation and collected into tubes containing an anticoagulant 
(EDTA) and stored on ice for up to 2 h prior to further processing. Blood was then diluted 1:1 
with phosphate buffered saline (PBS) 6 ml was layered over 3 ml of Lymhoprep (Axis 
Shield, Norway) and processed according to manufacturer’s instruction.  
Measurement of PARP activity 
PARP activity was measured by modification of a previously described method [8] validated 
to GCLP standard and used as a pharmacodynamic endpoint for clinical trials [9]. Briefly, 
maximally stimulated PARP activity was measured in triplicate samples of 104 cells 
permeabilised with ice-cold digitonin (0.15 mg/mL in water) in a reaction mixture containing 
350 µmol/L NAD+ as substrate in excess and 10 µg/mL PARP activating oligonucleotide 
(CGGAATTCCG) (Europrim, Invitrogen, UK) that mimics DNA strand breaks,  in a reaction 
buffer of 100 mmol/L Tris-HCl, 120 mmol/L MgCl2 (pH 7.8) in a final volume of 100 µL at 
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26°C in an oscillating water bath. The use of an oligonucleotide to maximally stimulate 
PARP minimises variation due to accidental activation of PARP by the unintentional 
induction of DNA breaks during PBMCs harvesting and processing. The reaction was 
stopped after 6 min. by the addition of excess PARP inhibitor (400 µL of 12.5 µmol/L 
AG014699) and the cells were blotted along with a poly(ADP-ribose) standard (0-25 pmol: 
Biomol, Exeter, UK) onto a nitrocellulose membrane (Hybond-N, Amersham, UK) using a 
purpose-built 48-well manifold. Following incubation with the primary anti-PAR 10H 
antibody 1:500 in PBS containing 5% non-fat powdered dried milk and 0.5% Tween 20 
(PBS-MT) overnight at 4°C then HRP-conjugated goat anti-mouse secondary antibody 
(1:1000 in PBS-MT; Dako, Ely, UK) for 1 hour at room temperature the membrane was 
exposed for 1 min. to enhanced chemiluminescence (ECL) reaction solution (Amersham, 
Little Chalford, UK) and chemiluminesence measured using a Fuji LAS3000 with imaging 
software (Fuji LAS Image version 1.1, Raytek). Results were expressed in light absorbtion 
units (LAU) relative to the number of cells loaded and subsequently calculated by reference 
to the poly(ADP-ribose) standard curve. 
Measurement of PARP-1 expression 
Briefly, the cell pellet was lysed in 100 µl of Laemmli buffer [10] with 1x Halt protease 
inhibitor cocktail (Thermo Fisher Scientific) resuspended on ice for 30 min. sonicated on ice 
for 10 s (Vibracell Sonicator, Sonics and Materials, Danbury, Conn.) and heated in loading 
dye containing β-mercaptoethanol and bromophenol blue at 95°C for 5 min. Lysates (30 µg 
of protein per lane) were loaded onto Tris-HCl 5-20% polyacrylamide gels (Bio-Rad, 
Hercules, CA) along with purified recombinant PARP-1 immunoblotting standard  (Biomol, 
Exeter, UK) and after electrophoresis at 100 V for 2 h (Criterion electrophoresis apparatus, 
Bio-Rad) the proteins were transferred for 1 h at 4°C into a nitrocellulose membrane 
(Hybond-C, Amersham, UK) using a Criterion Blotter (Bio-Rad). After blocking for 1 h in 
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PBS-MT the membrane was incubated overnight at 4°C with shaking with an anti-PARP-1 
C2-10 primary antibody (Trevigen, Gaithersburg, MD) diluted 1:2000 in PBS-MT, washed 3 
times for 15 min. in PBS containing 0.5% Tween20 (PBS-T), and then incubated with the 
HRP-linked secondary goat anti-mouse antibody (Dako) diluted 1:1000 in PBS-MT, washed 
again for 1 h in PBS-T with changing buffer every 5 min. then dried. The protein was 
visualised with ECL plus detection kit (Amersham) using the manufacturer’s protocol 
followed by chemiluminescence detection as described above. We quantified the PARP-1 
expression by reference to purified recombinant PARP-1 protein (Biomol) standard curve (0-
40 ng). This assay has also been validated to GCLP standard for evaluation of patient samples 
(E. Mulligan and T. Zaremba, unpublished data). 
Statistical analysis 
We analyzed each pooled sample in triplicate in three independent experiments (animals) or 
in duplicate (Western blot) and quadruplicate (PAR assay) in single experiment (humans). 
We calculated P-values for PARP activity comparison by the Student’s t-test using GraphPad 
Prism4 software (GraphPad, La Jolla, CA) and by Tukey’s test (Minitab, Coventry, UK).  
RESULTS  
Case presentation 
 
A 67 year old male patient presented in 2006 with a 7 - 8 cm left proximal vastus medialis 
mass in the left thigh mass, which incision biopsy showed a Trojani grade 3 soft tissue 
sarcoma of non specific type, and no evidence of metastatic disease. Subsequently, the patient 
had surgery to remove the tumour and received adjuvant radiotherapy (60 Gy in 30 fractions). 
In 2007 pulmonary metastases and intra-abdominal lymphadenopathy were detected and the 
patient received single agent DOX (142.5 mg/m2). Before the first cycle of chemotherapy the 
patient was consented for study. A blood sample was obtained and processed according to 
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local ethics committee.  The patient revealed that he had an identical twin brother who would 
be willing to donate a blood sample for the study as a healthy volunteer. The sample was 
obtained at the same time as the second sample from patient, which took place 3 weeks after 
administration of the first dose of DOX.  
PARP activity 
Measurement of PARP activity in PBMCs from the subjects showed that the mean PARP 
activity for the patient before the treatment was 160 pmol PAR/106 cells and for the healthy 
volunteer was 130 pmol PAR/106 cells. We observed an approximately 9-fold decrease  in 
PARP activity in a second sample from the patient taken 21 days after the first drug 
administration (17 pmol PAR/106 cells) (Fig. 1A, B). 
PARP-1 expression  
 
Measurement of PARP-1 expression in PBMCs from the subjects showed that the mean 
expression for the patient before the treatment was 0.15 ng PARP/µg total cellular protein 
while for the healthy volunteer was 0.2 ng PARP/µg total cellular protein. We observed a 
decrease in PARP-1 expression to below the limit of quantification in the patient sample 
taken after the first cycle of DOX treatment (Fig. 1C). 
 
PARP activity in mice treated with DOX 
 
The effects of DOX treatment (5 mg/kg) on PARP activity in PBMCs from mice 1 h, 24 h 
and 1 week after drug administration are shown in Fig. 2. We observed decrease in PARP 
activity 1 h after drug administration (63% control, range 50-88%; P<<0.05, Tukey’s test) 
and after 24 h (53% control, range 12-78%; P<<0.05, Tukey’s test). We observed restoration 
in PARP activity 1 week after DOX treatment (86% control, range 66-112%; P=0.24, 
Tukey’s test).  
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Discussion 
 
In this study we investigated the inter-individual variation in PARP activity and expression in 
subjects with the same genetic background i.e. homozygotic twins. We found that in the 
patient’s pre-treatment sample PARP activity and expression were similar to his identical 
brother. In both subjects PARP activity was within the range seen in the general population of 
healthy volunteers and cancer patients (10 - 2190 pmol/106 cells: TZ unpublished data). We 
showed that an identical genotype gave very similar phenotype and this finding must be taken 
into account in an ongoing discussion about the factors determining PARP activity in relation 
to PARP-1 expression in humans.  
We also found that after DOX treatment the patient had much lower PARP activity and 
PARP-1 expression. This observation suggested that DOX treatment may reduce both 
parameters.  
To confirm our findings we also investigated DOX treatment in an animal model: PARP 
activity was also suppressed in male mice treated with DOX (5 mg/kg) 1 and 24 h after drug 
administration (P<<0.05). However, the effect was more modest (approximately 2-fold) 
compared to the substantial (9-fold) reduction in the patient.  
Our finding with a decrease of PARP activity after DOX treatment is somewhat in contrast 
with previous data showing that cardiotoxicity of DOX is a result of oxidative stress (reactive 
oxygen species, ROS formation) where oxidative DNA breakage leads to PARP activation 
[11]. We hypothesize that DOX treatment, due to its selective toxicity to different subtypes of 
blood cells, altered the profile of the PBMCs (mostly lymphocytes) population and that the 
observed decrease in PARP activity could be due to selective killing of the population of cells 
with higher PARP activity by DOX.  Ranjit et al., [12] showed that different subtypes of 
PBMCs had different PARP-1 content with B lymphocytes (18-47% of lymphocytes) having 
the highest expression level (8.64 Units), compared with T lymphocytes (approx. 70% of 
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lymphocytes, 4.2 Units) and monocytes (3-8% of leukocytes, 2.2 Units). If the reason for 
high PARP-1 expression in B lymphocytes is associated with its role in DNA rearrangement 
necessary for the production of antibodies PARP activity in B cells may also be high. At least 
two studies showed that chemotherapy causes significant reduction in B lymphocyte count. 
Mackall et al., [13] demonstrated a rapid and severe decrease in B cell number to almost 
undetectable level after one cycle of chemotherapy (several different regimes including single 
agent cyclophosphamide and cyclophosphamide in combination with DOX and vincristine) 
and up to 6-fold decrease in number of T cells in 10 studied patients. Similarly, Hakim et al., 
[14] showed up to 96% reduction in B cells and >60% reduction of T cells after treatment 
with FLAC regime (DOX, 5-fluorouracil, cyclophosphamide). The full recovery in number of 
B lymphocytes was not observed until 3 months after the last cycle. These data suggest that 
chemotherapy leads to the depletion of several subtypes of PBMCs, especially B 
lymphocytes. The decrease in activity in the sarcoma patient treated with DOX could 
therefore be due to loss of PBMCs with high PARP-1 expression and PARP activity leaving 
the patient with those that naturally have less PARP-1 and lower activity. However, a larger 
study would be needed to confirm such an implication. The much greater effect of DOX in 
the patient than in the mice may reflect the time of sampling. If the high PARP-1 expressing 
cells are culled in a time-dependent fashion we may not have sampled the mouse PBMCs at 
the nadir and may have been only measuring the semi-acute effects of DOX on PARP 
activity rather than a combined effect on activity and selective killing of high PARP-1 
expressing cells. Further experiments are clearly warranted to determine the time-dependent 
effects of DOX on lymphocyte populations with different PARP-1 expression.  
This small study showed a profound decrease in PARP activity measured in PBMCs from a 
patient who underwent chemotherapy treatment. Our hypothesis, that this could be due to a 
selective depletion of B lymphocytes in blood, requires further investigation. This finding is 
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very important for current and future clinical studies and trials on PARP inhibitors where 
PARP activity is used as a pharmacodynamic endpoint; here we demonstrated that a decrease 
in PARP activity in such studies could be due to an effect of the chemotherapeutic, as well as 
the PARP inhibitor, on PBMCs and lead to a false impression of the effectiveness of the 
PARP inhibitor.  As a potential solution it would be beneficial to perform flow cytometry 
analysis to test the content of different cell subtypes and subsequently measure PARP activity 
in those cells. The difference in PARP activity before and after drug administration would 
give a real picture of effectiveness of tested therapy and also information on its toxicity to 
particular cell subtypes.  
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Legend to figures 
 
Figure 1: PARP activity and expression measured in PBMCs from the patient before and 
after 1st cycle of DOX treatment and from the healthy volunteer (control subject).  
Panel A: PAR formation detected by immunoblot assay. First row of dots show results for 
25, 10, 5, 1, 0.2, 0 pmol PAR standard and positive reaction for quality control sample of 
L1210 cells (positive control). Dots in rows I-III show PAR formation in PBMCs from the 
patient before and after DOX treatment, row III show PAR formation in PBMCs from 
healthy subject.  
Panel B: Semi-quantitative analysis of the results of the experiment shown in A: mean value 
for data from single experiment where each sample was measured in quadruplicate, error bars 
represent SEM.  
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Panel C: PARP-1 expression measured by semi-quantitative Western blot. Bands on the left-
hand side of the blot: BT, patient’s sample taken before DOX treatment; AT, patient’s sample 
taken after DOX treatment; HV, healthy volunteer’s (sibling) sample. Bands on the right-hand 
side of the blot: positive reaction for quality control sample (QC) of K562 cells (quality 
control, QC) and 0, 1, 2.5, 5, 10, 25, 40 ng of recombinant PARP-1 standard. MW, molecular 
weight marker. 
 
Figure 2: Effects of DOX treatment on the PARP activity in PBMCs from male mice.  
Panel A: PAR formation detected by immunoblot assay.  
Panel B: Analysis of the results from three independent experiments where samples are 
assayed in triplicate. Data are expressed as percentage control.   
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